Advertisement

Topics

Companies Related to "Adverse prognostic value expression primary resected pulmonary squamous" [Most Relevant Company Matches] RSS

07:17 EST 15th December 2017 | BioPortfolio

Here are the most relevant search results for "Adverse prognostic value expression primary resected pulmonary squamous" found in our extensive corporate database of over 50,000 company records.

Showing "Adverse prognostic value expression primary resected pulmonary squamous" Companies 1–25 of 1,400+

Relevant

ChipDX LLC

ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology research use only. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays through collaborations with existing diagnostic service providers and also through its modular, online delivery system: www.ChipDX.com. Other ...


Cystic Fibrosis Enters the Proteomics Scene

As a continuation to genomic research, proteomics now offers the unique advantage to examine global alterations in the protein expression patterns of CF cells and tissues. The systematic use of proteomics should ultimately result in the finding of new prognostic markers...

Agendia BV

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test -- MammaPrint(R) -- that predicts the risk of breast cancer rec...


Pulmonary Hypertension Association (PHA)

Headquartered in Silver Spring, Md., PHA is the country’s leading organization connecting pulmonary hypertension patients, families, and medical professionals. Its mission is to find ways to prevent and cure pulmonary hypertension and provide hope for the community through support, education, advocacy and awareness. PHA provides free access to informa...

VIDA Diagnostics, Inc.

VIDA Diagnostics is a leader in quantitative pulmonary image analysis for the diagnosis and treatment of pulmonary diseases. VIDA Diagnostics develops and commercializes pulmonary applications, establishing quantitative pulmonary imaging in routine clinical practice. VIDA is an established leader in quantitative lung analysis for COPD, emphysema and asthma, establishing objective, quantitative me...

Pulmonary Hypertension Association

Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy. Approximately 100,000 people in Europe and the United S...

Oxford Expression Technologies

Oxford Expression Technologies is a world-renowned centre of excellence for baculovirus protein expression. We provide protein expression products, services and consultancy to many global pharmaceutical companies and are now marketing commercial products based upon our world-beating flashBAC protein expression technologyOET was founded in 2000 by leading members of the School of Biological and Mol...

InteRNA Technologies B.V.

InteRNA Technologies B.V. actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The company's primary focus is to unravel the role of its proprietary miRNAs in cancer.

InteRNA Technologies BV

InteRNA Technologies B.V. actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The company's primary focus is to unravel the role of its proprietary miRNAs in cancer.

AdverseEvents, Inc.

AdverseEvents, Inc. (AEI) is the first service provider to deliver accurate, real-time information on adverse drug events reported to the FDA. AEI utilizes a unique data sourcing method called RxFilter™, a proprietary 17-step data refinement process that standardizes and normalizes the data from the FDA’s Adverse Event Reporting System (AERS) int...

Metamark Genetics, Inc.

Metamark is a privately held oncology company focused on the development of function-based prognostic assays for early staged cancers. The MetamarkDx(TM) Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants(TM), genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For furthe...

Synspira

Synspira is developing a new class of inhalable glycopolymer-based therapeutics that disrupt mucus accumulation and biofilm invasion, which are key drivers of pulmonary diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia. Synspira has an exclusive license from Synedgen to the Glycomics Technology Platform fo...

Coalition for Pulmonary Fibrosis

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thir...

BiomarkerBase

BiomarkerBase™ (http://www.biomarkerbase.com) includes every molecular biomarker on a drug label, every biomarker in a PMA-approved diagnostic, prognostic, or companion diagnostic (theranostic) test, and every biomarker in an active phase 3 or 4 clinical drug trial. All records in BiomarkerBase™ are linked directly to primary authorities such as ...

Genomic Expression, Inc.

Genomic Expression’s mission is to save lives and to make the delivery of healthcare more effective. The inconvenient truth is that only one out of four cancer treatments prolong life. Genomic Expression aims to change this by helping doctors select the best drug for their patients, by leveraging it’s clinically focused RNA sequencing technology called ...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells...

Expression Analysis, Inc.

Expression Analysis (www.ExpressionAnalysis.com) provides whole genome to focused set gene expression and genotyping assays along with DNA sequencings services, sequence enrichment technologies and bioinformatics support. Platforms utilized include Affymetrix GeneChip® and GeneTitan®, Applied Biosystems’ Taqman, Illumina BeadChip® and Genome ...

Genometry, Inc.

GENOMETRY, INC. is a life-science platform-technology company commercializing and popularizing a revolutionary high-throughput gene-expression profiling method for next-generation pharmaceutical discovery applications. L1000™ Expression Profiling produces gene-expression profiles at a rate of thousands a day and at only a fraction of the cost of conve...

The Pulmonary Fibrosis Foundation

The Pulmonary Fibrosis Foundation is 501©(3) organization, whose mission is to find a cure for idiopathic pulmonary fibrosis (IPF) by funding research, advocating for IPF issues, promoting disease awareness, and providing a compassionate environment for supporting patients and their loved ones. We achieve these goals by promoting new research through increased funding; by representing the needs o...

Spiros Development Corporation

Spiros Development Corporation develops the Spiros-Registered Trademark-, a dry powder pulmonary drug delivery system, and to conduct formulation work, clinical trials and commercialization for certain specified leading asthma and chronic obstructive pulmonary disease ("COPD") drugs for use with Spiros.

Dako Australia

makers of automated, predictive,diagnostic, and prognostic cancer systems.

Imgenex

Our goal is to provide quality reagents at affordable price for biomedical research. We also provide custom services for baculovirus, bacterial, and mammalian gene expression. Recently, we have introduced a retroviral expression system.

EvergreenHealth

EvergreenHealth, a public hospital district and community-based healthcare organization established in 1972, offers a breadth of services and programs that is among the most comprehensive in the region. More than 950 physicians provide clinical excellence within more than 80 specialties, including cardiac, oncology, surgical care, orthopedics, a neuroscien...

Chrysalis Technologies

Chrysalis Technologies was established in 2000 as a first-tier subsidiary of the Altria Group, Inc. The company, which now operates as a division of Philip Morris USA, has developed the soft-mist aerosol technology platform for pulmonary drug delivery and is focused on the development and commercialization of the portable inhaler based on this technology. The Company seeks to establish pharmaceuti...


More From BioPortfolio on "Adverse prognostic value expression primary resected pulmonary squamous"

Quick Search
Advertisement
 

Corporate Database Quicklinks